SCHEMBL19715004

SCHEMBL19715004

NC(CC(=O)O)C(=O)Nc1cccc(N(CCCl)CCCl)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LTA4H P09960 2/20 0.44
▸ IDO1 P14902 1/20 0.43
▸ CYP3A4 P08684 3/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ ALOX15 P16050 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ HIF1A Q16665 2/20 0.43
▸ LMNA P02545 2/20 0.43
▸ ABCB11 O95342 1/20 0.43
▸ CHRM2 P08172 1/20 0.43
▸ ADRA2A P08913 1/20 0.43
▸ CHRM1 P11229 1/20 0.43
▸ ACHE P22303 1/20 0.43
▸ PTGS1 P23219 1/20 0.43
▸ OPRM1 P35372 1/20 0.43
▸ DRD3 P35462 1/20 0.43
▸ SLC6A3 Q01959 1/20 0.43
▸ KCNH2 Q12809 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ CYP1A2 P05177 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18428012 1.00 LTA4H (0.44) LTA4HIDO1CYP3A4ALDH1A1ALOX15
SCHEMBL18428056 0.81 CYP3A4 (0.44) LTA4HIDO1CYP3A4ALDH1A1ALOX15
SCHEMBL18428002 0.79 IDO1 (0.44) IDO1CYP3A4ALDH1A1ALOX15SMN1; SMN2
SCHEMBL16970727 0.79 IDO1 (0.44) IDO1CYP3A4ALDH1A1ALOX15SMN1; SMN2
SCHEMBL19715008 0.79 IDO1 (0.44) IDO1CYP3A4ALDH1A1ALOX15SMN1; SMN2
SCHEMBL19715035 0.77 EGFR (0.46) IDO1CYP3A4ALDH1A1ALOX15SMN1; SMN2
SCHEMBL18428058 0.77 EGFR (0.46) IDO1CYP3A4ALDH1A1ALOX15SMN1; SMN2
SCHEMBL19715048 0.77 HDAC4 (0.49) —
SCHEMBL18428104 0.77 HDAC4 (0.49) —
SCHEMBL3954076 0.75 LTA4H (0.67) LTA4HALDH1A1SMN1; SMN2LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108026026-B Beta-substituted beta-amino acids and analogs as chemotherapeutic agents and uses thereof 夸德里加生物科学公司 2021-02-09 — — CN disclosed
US-10017459-B2 β-substituted β-amino acids and analogs as chemotherapeutic agents and uses thereof QUADRIGA BIOSCIENCES, INC. (US) 2018-07-10 — — US disclosed
US-20170362166-A1 BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS AND USES THEREOF QUADRIGA BIOSCIENCES, INC. 2017-12-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10017459-B2 β-substituted β-amino acids and analogs as chemotherapeutic agents and uses thereof SLC7A1, SLC3A2, SLC43A1 LTA4H 1812/4885IDO1 1311/4885CYP3A4 2058/4885
US-20170362166-A1 BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS AND USES THEREOF SLC3A2, SLC7A1, SLC43A1 LTA4H 1832/4885IDO1 1294/4885CYP3A4 2071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback